跳到正文
心血管健康证据综述4 分钟阅读

降压治疗对多数年龄段都降低心血管事件,85岁以上证据不明确

MoveVitals 编辑部 · 研究发表 · 解读更新

原文:Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. · Lancet (London, England) · 2021 · 论文原文 ↗

先看重点

汇总51项试验、358707名参与者的数据,收缩压每降低5 mm Hg,55至84岁人群的主要心血管事件风险比约为0.91,而85岁及以上人群未见明确获益(风险比0.99,95%置信区间0.87-1.12)。85岁及以上仅4788人,因此最高龄组的结论最不确定。

证据类型

证据综述

解读依据

公开摘要

阅读重点

方法与适用范围

研究在问什么

过去指南常以年龄和血压界值决定谁需要降压药,但对70岁以上人群和血压升高不明显的人,证据并不充分。作者检验了降压对主要心血管事件的作用是否随年龄和基线血压而不同。

研究了谁,如何研究

个体参与者数据荟萃分析,纳入来自血压降低治疗试验者协作组的随机对照试验,比较降压药与安慰剂、其他类别降压药,或强化与非强化降压策略,每组随访至少1000人年,排除既往心力衰竭者。参与者按年龄(<55岁、55-64岁、65-74岁、75-84岁、85岁及以上)和基线收缩压、舒张压(以10 mm Hg为一档)分组。采用按试验分层的固定效应一步法Cox模型。主要结局为致死或非致死性卒中、心肌梗死或缺血性心脏病、导致死亡或住院的心力衰竭的复合终点。

主要发现

以下为作者报告的结果。数字须连同人群和不确定性一起阅读。

  1. 1
    共纳入51项试验的358707名参与者,年龄中位数65岁(四分位距59-75,范围21至105岁):<55岁42960人(12.0%),55-64岁128437人(35.8%),65-74岁128506人(35.8%),75-84岁54016人(15.1%),85岁及以上4788人(1.3%)。
  2. 2
    收缩压每降低5 mm Hg,主要心血管事件的风险比在<55岁为0.82(95%置信区间0.76-0.88),55-64岁为0.91(0.88-0.95),65-74岁为0.91(0.88-0.95),75-84岁为0.91(0.87-0.96),85岁及以上为0.99(0.87-1.12)(校正后交互作用P=0.050)。舒张压降低3 mm Hg呈相似模式。
  3. 3
    绝对风险降低在高龄组更大(校正后交互作用P=0.024)。
  4. 4
    作者未发现各年龄组中相对获益随基线血压不同而有临床意义的差异,血压低至120/70 mm Hg以下时亦然。

局限与不确定性

  1. 1
    85岁及以上人数少,该组区间(0.87-1.12)既可能有获益也可能无获益。
  2. 2
    年龄与疗效的交互作用只是临界水平(P=0.050),对年龄组之间的差异应谨慎解读。
  3. 3
    纳入的是每组至少1000人年的试验,并排除既往心力衰竭者,结果未必适用于临床中所有人群。
  4. 4
    本解读仅基于摘要。

对日常健康的启示

汇总的试验提示,降压药在很宽的年龄和基线血压范围内都降低了心血管事件,单凭年龄不应排除治疗。85岁以后的证据最弱。是否治疗、如何治疗应与医生结合个人情况决定。

如何联系自己的数据

在家用血压计、每次在相同条件下测量,有助于你和医生了解血压是否在朝目标变化。不要仅凭血压计数值自行调整药物,复诊时带上记录即可。

如何理解这类证据

先看纳入了哪些设计、检索与偏倚评估如何完成,以及检索截止日期;发表新不代表底层证据都是最新的。

作者的结构化摘要 English

以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。

Background

The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline.

Methods

We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55-64 years, 65-74 years, 75-84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission.

Findings

We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59-75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55-64 years, 128 506 (35·8%) 65-74 years, 54 016 (15·1%) 75-84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm Hg reduction in systolic blood pressure for each age group were 0·82 (95% CI 0·76-0·88) in individuals younger than 55 years, 0·91 (0·88-0·95) in those aged 55-64 years, 0·91 (0·88-0·95) in those aged 65-74 years, 0·91 (0·87-0·96) in those aged 75-84 years, and 0·99 (0·87-1·12) in those aged 85 years and older (adjusted p_(interaction)=0·050). Similar patterns of proportional risk reductions were observed for a 3 mm Hg reduction in diastolic blood pressure. Absolute risk reductions for major cardiovascular events varied by age and were larger in older groups (adjusted p_(interaction)=0·024). We did not find evidence for any clinically meaningful heterogeneity of relative treatment effects across different baseline blood pressure categories in any age group.

Interpretation

Pharmacological blood pressure reduction is effective into old age, with no evidence that relative risk reductions for prevention of major cardiovascular events vary by systolic or diastolic blood pressure levels at randomisation, down to less than 120/70 mm Hg. Pharmacological blood pressure reduction should, therefore, be considered an important treatment option regardless of age, with the removal of age-related blood-pressure thresholds from international guidelines.

Funding

British Heart Foundation, National Institute of Health Research Oxford Biomedical Research Centre, Oxford Martin School.

来源与署名

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.

Blood Pressure Lowering Treatment Trialists' Collaboration.

Lancet (London, England) · 2021-08-27

DOI: 10.1016/s0140-6736(21)01921-8 ↗PubMed · 34461040 ↗Europe PMC · 记录的开放许可: cc by ↗

摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。

MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅

来源核验日期 2026-11-01

实用健康指南

放在一起读

·观察研究荟萃分析

昼夜活动节律紊乱与更高的死亡风险相关(109,365人)

在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。

Journal of the American Heart Association

重点论文精讲阅读论文 →
·随机试验荟萃分析

五类运动都降低了静息血压,等长训练降幅最大

汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。

British Journal of Sports Medicine

重点论文精讲阅读论文 →
·随机对照试验

盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降

在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。

The New England Journal of Medicine

重点论文精讲阅读论文 →
·测量验证研究/综述

智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤

在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。

The New England Journal of Medicine

重点论文精讲阅读论文 →
心血管健康 →